# Willemien J. van Driel

Source: https://onco.cc/people/willemien-van-driel/  
OnCo record `willemien-van-driel` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led OVHIPEC-1, the trial that showed heated intraperitoneal chemotherapy at surgery extends survival in ovarian cancer.

## Summary

Willemien van Driel was principal investigator of OVHIPEC-1, the Dutch randomised trial showing that adding hyperthermic intraperitoneal cisplatin to interval cytoreductive surgery improves recurrence-free and overall survival in stage III ovarian cancer, the first level-one evidence for HIPEC in the disease. She leads OVHIPEC-2 in the primary surgery setting.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: ovarian; surgery; hipec
- Role: Gynaecologic Oncologist, Netherlands Cancer Institute
- Specialisms: Ovarian cancer surgery; HIPEC; Interval cytoreduction

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=van%20Driel%20WJ%5BAuthor%5D%20HIPEC%20ovarian

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/)
- institutions: [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/)
- trials: [OVHIPEC-1](https://onco.cc/trials/ovhipec-1/)

---
JSON: https://onco.cc/api/v1/entities/willemien-van-driel.json